Kristen Bibeau1, Luis Féliz2, Christine F Lihou1, Haobo Ren1, Ghassan K Abou-Alfa3,4. 1. Incyte Corporation, Wilmington, DE. 2. Incyte Biosciences International Sàrl, Morges, Switzerland. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Weill Medical College, Cornell University, New York, NY.
Abstract
PURPOSE: Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced/metastatic CCA before enrollment in the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376). PATIENTS AND METHODS: Patients with locally advanced or metastatic CCA with FGFR2 fusions/rearrangements (n = 107), other FGF/FGFR alterations (n = 20), or no FGF/FGFR alterations (n = 18) and documented disease progression after at least one systemic cancer therapy before enrollment in FIGHT-202 were assessed. Prior therapy and disease response data were collated from electronic case report forms. PFS was calculated for each prior line of systemic cancer therapy. RESULTS: Among patients with FGFR2 fusions/rearrangements, other FGF/FGFR alterations, and no FGF/FGFR alterations, respectively, the median PFS with prior first-line systemic therapy was 5.5 months (95% CI, 4.0 to 8.0; n = 102), 4.4 months (2.7 to 7.1; n = 19), and 2.8 months (1.6 to 11.3; n = 16); the median PFS with prior second-line systemic therapy was 4.2 months (3.0 to 5.3; n = 39), 3.0 months (1.1 to 9.9; n = 8), and 5.9 months (2.4 to 12.5; n = 6). The median PFS was 7.0 months (4.9 to 11.1) for patients with FGFR2 fusions/rearrangements (n = 65) with second-line pemigatinib received during the FIGHT-202 trial. CONCLUSION: In patients with CCA and FGFR2 fusions or rearrangements, second-line treatment with pemigatinib may be associated with longer PFS compared with second-line treatment with systemic therapy received before study enrollment; however, a prospective controlled trial is required to confirm this. The results support the therapeutic potential of pemigatinib previously demonstrated in FIGHT-202.
PURPOSE: Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced/metastatic CCA before enrollment in the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376). PATIENTS AND METHODS: Patients with locally advanced or metastatic CCA with FGFR2 fusions/rearrangements (n = 107), other FGF/FGFR alterations (n = 20), or no FGF/FGFR alterations (n = 18) and documented disease progression after at least one systemic cancer therapy before enrollment in FIGHT-202 were assessed. Prior therapy and disease response data were collated from electronic case report forms. PFS was calculated for each prior line of systemic cancer therapy. RESULTS: Among patients with FGFR2 fusions/rearrangements, other FGF/FGFR alterations, and no FGF/FGFR alterations, respectively, the median PFS with prior first-line systemic therapy was 5.5 months (95% CI, 4.0 to 8.0; n = 102), 4.4 months (2.7 to 7.1; n = 19), and 2.8 months (1.6 to 11.3; n = 16); the median PFS with prior second-line systemic therapy was 4.2 months (3.0 to 5.3; n = 39), 3.0 months (1.1 to 9.9; n = 8), and 5.9 months (2.4 to 12.5; n = 6). The median PFS was 7.0 months (4.9 to 11.1) for patients with FGFR2 fusions/rearrangements (n = 65) with second-line pemigatinib received during the FIGHT-202 trial. CONCLUSION: In patients with CCA and FGFR2 fusions or rearrangements, second-line treatment with pemigatinib may be associated with longer PFS compared with second-line treatment with systemic therapy received before study enrollment; however, a prospective controlled trial is required to confirm this. The results support the therapeutic potential of pemigatinib previously demonstrated in FIGHT-202.
Authors: Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: Maeve A Lowery; Laura W Goff; Bridget P Keenan; Emmet Jordan; Rui Wang; Andrea G Bocobo; Joanne F Chou; Eileen M O'Reilly; James J Harding; Nancy Kemeny; Marianela Capanu; Ann C Griffin; Joseph McGuire; Alan P Venook; Ghassan K Abou-Alfa; Robin K Kelley Journal: Cancer Date: 2019-08-27 Impact factor: 6.860
Authors: Andrea A Florio; Jacques Ferlay; Ariana Znaor; David Ruggieri; Christian S Alvarez; Mathieu Laversanne; Freddie Bray; Katherine A McGlynn; Jessica L Petrick Journal: Cancer Date: 2020-03-04 Impact factor: 6.921
Authors: Phillip C C Liu; Holly Koblish; Liangxing Wu; Kevin Bowman; Sharon Diamond; Darlise DiMatteo; Yue Zhang; Michael Hansbury; Mark Rupar; Xiaoming Wen; Paul Collier; Patricia Feldman; Ronald Klabe; Krista A Burke; Maxim Soloviev; Christine Gardiner; Xin He; Alla Volgina; Maryanne Covington; Bruce Ruggeri; Richard Wynn; Timothy C Burn; Peggy Scherle; Swamy Yeleswaram; Wenqing Yao; Reid Huber; Gregory Hollis Journal: PLoS One Date: 2020-04-21 Impact factor: 3.240
Authors: Angela Lamarca; Daniel H Palmer; Harpreet Singh Wasan; Paul J Ross; Yuk Ting Ma; Arvind Arora; Stephen Falk; Roopinder Gillmore; Jonathan Wadsley; Kinnari Patel; Alan Anthoney; Anthony Maraveyas; Tim Iveson; Justin S Waters; Claire Hobbs; Safia Barber; W David Ryder; John Ramage; Linda M Davies; John A Bridgewater; Juan W Valle Journal: Lancet Oncol Date: 2021-03-30 Impact factor: 41.316
Authors: Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan Journal: Gut Date: 2012-08-15 Impact factor: 23.059